Trials / Completed
CompletedNCT00328458
EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients
A Phase I, Open-label, Dose-escalation, Safety Study of the Combination of EPO906 and Radiation Therapy for the Treatment of Patients With Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety of the drug EPO906 that could shrink tumors when used with radiation therapy in cancer patients.
Detailed description
* To determine the maximum tolerated dose (MTD) of EPO906 administered in combination with radiation therapy and establish a recommend phase II dose. * To evaluate the safety and toxicity profile of EPO906 when administered concurrently with radiotherapy in three disease cohorts. * To evaluate tumor response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EPO906 (epothilone B) |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2008-05-01
- Completion
- 2009-07-01
- First posted
- 2006-05-22
- Last updated
- 2025-05-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00328458. Inclusion in this directory is not an endorsement.